Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring

76Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.
Get full text

Abstract

A double‐blind controlled trial of oral hydroxychloroquine (HC) treatment in polymorphic light eruption (PLE) was completed in 13 patients on active treatment and 15 on placebo during June, July and August 1982. HC dose was 400 mg daily for the first month and 200 mg daily thereafter. Exposure to ambient solar ultraviolet radiation (UVR) was monitored throughout the trial by polysulphone film lapel badges. Patients scored their symptoms on a visual analogue scale. Drug concentration was monitored in plasma and hair, and oculotoxicity was assessed by visual contrast sensitivity. Moderate clinical improvement occurreds associated with a statistically significant improvement in skin rash (P < 0.01). Copyright © 1987, Wiley Blackwell. All rights reserved

Cite

CITATION STYLE

APA

MURPHY, G. M., HAWK, J. L. M., & MAGNUS, I. A. (1987). Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. British Journal of Dermatology, 116(3), 379–386. https://doi.org/10.1111/j.1365-2133.1987.tb05852.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free